{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T06:09:44Z","timestamp":1774678184112,"version":"3.50.1"},"reference-count":168,"publisher":"Elsevier","isbn-type":[{"value":"9780443343858","type":"print"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/bs.irn.2025.02.003","type":"book-chapter","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T11:17:58Z","timestamp":1747999078000},"page":"99-148","source":"Crossref","is-referenced-by-count":1,"title":["Clinical pharmacology"],"prefix":"10.1016","author":[{"given":"Severin B.","family":"Vogt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias E.","family":"Liechti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/bs.irn.2025.02.003_bib1","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/0091-3057(85)90022-X","article-title":"Patterns of exploration in rats distinguish lisuride from lysergic acid diethylamide","volume":"23","author":"Adams","year":"1985","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"key":"10.1016\/bs.irn.2025.02.003_bib2","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1016\/0006-2952(69)90185-3","article-title":"Metabolism of 5-methoxy-N,N dimethyltryptamine-14C in the rat","volume":"18","author":"Agurell","year":"1969","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib3","doi-asserted-by":"crossref","first-page":"1302559","DOI":"10.3389\/fpsyt.2023.1302559","article-title":"Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: A controlled trial in healthy subjects","volume":"14","author":"Aicher","year":"2023","journal-title":"Frontiers in Psychiatry"},{"key":"10.1016\/bs.irn.2025.02.003_bib4","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S2213-8587(23)00120-1","article-title":"Oxytocin in response to MDMA provocation test in patients with arginine vasopressin deficiency (central diabetes insipidus): A single-centre, case-control study with nested, randomised, double-blind, placebo-controlled crossover trial","volume":"11","author":"Atila","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/bs.irn.2025.02.003_bib5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.45278","article-title":"Oxytocin and the role of fluid restriction in MDMA-induced hyponatremia: A secondary analysis of four randomized clinical trials","volume":"7","author":"Atila","year":"2024","journal-title":"JAMA Network Open"},{"key":"10.1016\/bs.irn.2025.02.003_bib6","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/(SICI)1098-2396(200005)36:2<102::AID-SYN3>3.0.CO;2-#","article-title":"Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: Therapeutic implications","volume":"36","author":"Baumann","year":"2000","journal-title":"Synapse"},{"key":"10.1016\/bs.irn.2025.02.003_bib7","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/cpt.2487","article-title":"Acute effects of psilocybin after escitalopram or placebo pretreatment in a randomized, double-blind, placebo-controlled, crossover study in healthy subjects","volume":"111","author":"Becker","year":"2022","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/bs.irn.2025.02.003_bib8","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1002\/cpt.3618","article-title":"Acute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre-Administration in a Randomized, Double-Blind, Cross-Over Phase I Trial","volume":"117","author":"Becker","year":"2025","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/bs.irn.2025.02.003_bib9","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/ijnp\/pyac075","article-title":"Ketanserin reverses the acute response to LSD in a randomized, double-blind, placebo-controlled, crossover study in healthy participants","volume":"26","author":"Becker","year":"2023","journal-title":"The International Journal of Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib10","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.biopsych.2010.08.003","article-title":"Is ecstasy an \u201cempathogen\u201d? Effects of\u00b13,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others","volume":"68","author":"Bedi","year":"2010","journal-title":"Biological Psychiatry"},{"key":"10.1016\/bs.irn.2025.02.003_bib11","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1111\/j.1360-0443.2010.02948.x","article-title":"Rediscovering MDMA (ecstasy): The role of the American chemist Alexander T. Shulgin","volume":"105","author":"Benzenh\u00f6fer","year":"2010","journal-title":"Addiction"},{"key":"10.1016\/bs.irn.2025.02.003_bib12","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1124\/mol.54.1.94","article-title":"Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: Evidence for agonist-directed trafficking of receptor stimulus","volume":"54","author":"Berg","year":"1998","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib13","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1177\/0269881116663120","article-title":"The effects of MDMA on socio-emotional processing: Does MDMA differ from other stimulants?","volume":"30","author":"Bershad","year":"2016","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib14","first-page":"3452691","article-title":"Acute intoxication following dimethyltryptamine ingestion","author":"Bilhimer","year":"2018","journal-title":"Case Reports in Emergency Medicine"},{"key":"10.1016\/bs.irn.2025.02.003_bib15","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: A randomized clinical trial","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/bs.irn.2025.02.003_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.110367","article-title":"The potential use of N-methyl-3,4-methylenedioxyamphetamine (MDMA) assisted psychotherapy in the treatment of eating disorders comorbid with PTSD","volume":"146","author":"Brewerton","year":"2021","journal-title":"Medical Hypotheses"},{"key":"10.1016\/bs.irn.2025.02.003_bib17","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s40262-017-0540-6","article-title":"Pharmacokinetics of escalating doses of oral psilocybin in healthy adults","volume":"56","author":"Brown","year":"2017","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/bs.irn.2025.02.003_bib18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0378-4347(01)00386-3","article-title":"Determination of LSD and its metabolites in human biological fluids by high-performance liquid chromatography with electrospray tandem mass spectrometry","volume":"765","author":"Canezin","year":"2001","journal-title":"Journal of Chromatography. B, Biomedical Sciences and Applications"},{"key":"10.1016\/bs.irn.2025.02.003_bib19","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.irn.2025.02.003_bib20","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/01.fpc.0000230419.05221.fc","article-title":"Influence of CYP2D6 polymorphism on 3,4-methylenedioxymethamphetamine (\u2018Ecstasy\u2019) cytotoxicity","volume":"16","author":"Carmo","year":"2006","journal-title":"Pharmacogenetics and Genomics"},{"key":"10.1016\/bs.irn.2025.02.003_bib21","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1021\/acschemneuro.8b00215","article-title":"Dark classics in chemical neuroscience: Mescaline","volume":"9","author":"Cassels","year":"2018","journal-title":"ACS Chemical Neuroscience"},{"key":"10.1016\/bs.irn.2025.02.003_bib22","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejphar.2008.07.040","article-title":"Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq\/11 activation and calcium mobilisation in CHO cells","volume":"594","author":"Cussac","year":"2008","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib23","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1038\/s41386-022-01344-y","article-title":"Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder","volume":"47","author":"D\u2019Souza","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib24","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1007\/s00213-018-5010-9","article-title":"Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: A randomized, double-blind, placebo-controlled pilot study","volume":"235","author":"Danforth","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/bs.irn.2025.02.003_bib25","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/bs.irn.2025.02.003_bib26","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1177\/0269881118769063","article-title":"The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption","volume":"32","author":"Davis","year":"2018","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"key":"10.1016\/bs.irn.2025.02.003_bib152","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00007691-200404000-00009","article-title":"Human pharmacology of MDMA: Pharmacokinetics, metabolism, and disposition","volume":"26","author":"de la Torre","year":"2004","journal-title":"Therapeutic Drug Monitoring"},{"key":"10.1016\/bs.irn.2025.02.003_bib27","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1080\/03602532.2016.1278228","article-title":"Metabolism of psilocybin and psilocin: Clinical and forensic toxicological relevance","volume":"49","author":"Dinis-Oliveira","year":"2017","journal-title":"Drug Metabolism Reviews"},{"key":"10.1016\/bs.irn.2025.02.003_bib28","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2174\/1874467211666181010154139","article-title":"Pharmacokinetic and pharmacodynamic aspects of Peyote and mescaline: Clinical and forensic repercussions","volume":"12","author":"Dinis-Oliveira","year":"2019","journal-title":"Current Molecular Pharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.22265","article-title":"Development and validation of an LC-MS\/MS method to quantify lysergic acid diethylamide (LSD), iso-LSD, 2-oxo-3-hydroxy-LSD, and nor-LSD and identify novel metabolites in plasma samples in a controlled clinical trial","volume":"32","author":"Dolder","year":"2018","journal-title":"Journal of Clinical Laboratory Analysis"},{"key":"10.1016\/bs.irn.2025.02.003_bib30","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.brainresbull.2016.03.002","article-title":"Ayahuasca: Pharmacology, neuroscience and therapeutic potential","volume":"126","author":"Dominguez-Clave","year":"2016","journal-title":"Brain Research Bulletin"},{"key":"10.1016\/bs.irn.2025.02.003_bib31","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.amjcard.2007.06.045","article-title":"Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease","volume":"100","author":"Droogmans","year":"2007","journal-title":"The American Journal of Cardiology"},{"key":"10.1016\/bs.irn.2025.02.003_bib32","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/17470910802649470","article-title":"Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration","volume":"4","author":"Dumont","year":"2009","journal-title":"Social Neuroscience"},{"key":"10.1016\/bs.irn.2025.02.003_bib33","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.etp.2008.03.005","article-title":"5-Hydroxytryptamine (5-HT)-induced valvulopathy: Compositional valvular alterations are associated with 5-HT2B receptor and 5-HT transporter transcript changes in Sprague-Dawley rats","volume":"60","author":"Elangbam","year":"2008","journal-title":"Experimental and Toxicologic Pathology"},{"key":"10.1016\/bs.irn.2025.02.003_bib950","article-title":"Acute dose-dependent effects and self-guided titration of continuous N,N-Dimethyltryptamine infusions in a double-blind placebo-controlled study in healthy subjects","author":"Erne","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.euroneuro.2023.12.006","article-title":"Safety and tolerability of inhaled N,N-dimethyltryptamine (BMND01 candidate): A phase I clinical trial","volume":"80","author":"Falchi-Carvalho","year":"2024","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib35","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1124\/jpet.107.129056","article-title":"Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: Pharmacological effects and pharmacokinetics","volume":"323","author":"Farre","year":"2007","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/bs.irn.2025.02.003_bib36","doi-asserted-by":"crossref","DOI":"10.1096\/fasebj.2019.33.1_supplement.502.3","article-title":"\u03b2-Arrestins mediate rapid 5-HT2A receptor endocytosis to regulate intensity and duration of signaling","volume":"33","author":"Felsing","year":"2019","journal-title":"The FASEB Journal"},{"key":"10.1016\/bs.irn.2025.02.003_bib37","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.psyneuen.2016.08.011","article-title":"Urinary and plasma oxytocin changes in response to MDMA or intranasal oxytocin administration","volume":"74","author":"Francis","year":"2016","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/bs.irn.2025.02.003_bib38","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/0269881121991822","article-title":"Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches","volume":"35","author":"Garcia-Romeu","year":"2021","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib39","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","article-title":"Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases","volume":"202","author":"Gasser","year":"2014","journal-title":"The Journal of Nervous and Mental Disease"},{"key":"10.1016\/bs.irn.2025.02.003_bib40","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1021\/acsptsci.3c00192","article-title":"Comparative pharmacological effects of lisuride and lysergic acid diethylamide revisited","volume":"7","author":"Glatfelter","year":"2024","journal-title":"ACS Pharmacology & Translational Science"},{"key":"10.1016\/bs.irn.2025.02.003_bib41","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11419-011-0131-4","article-title":"Oxidation of lysergic acid diethylamide (LSD) by peroxidases: A new metabolic pathway","volume":"30","author":"Gomes","year":"2012","journal-title":"Forensic Toxicology"},{"key":"10.1016\/bs.irn.2025.02.003_bib42","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.neuron.2007.01.008","article-title":"Hallucinogens recruit specific cortical 5-HT2A receptor-mediated signaling pathways to affect behavior","volume":"53","author":"Gonzalez-Maeso","year":"2007","journal-title":"Neuron"},{"key":"10.1016\/bs.irn.2025.02.003_bib43","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s13318-023-00822-y","article-title":"Pharmacokinetics of N,N-dimethyltryptamine in Humans","volume":"48","author":"Good","year":"2023","journal-title":"European Journal of Drug Metabolism and Pharmacokinetics"},{"key":"10.1016\/bs.irn.2025.02.003_bib44","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression","volume":"387","author":"Goodwin","year":"2022","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.irn.2025.02.003_bib45","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/s41386-023-01648-7","article-title":"Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication","volume":"48","author":"Goodwin","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib46","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1055\/s-2005-916185","article-title":"Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): A double-blind, cross-over study in healthy volunteers","volume":"38","author":"Gouzoulis-Mayfrank","year":"2005","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/bs.irn.2025.02.003_bib47","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib48","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00213-011-2358-5","article-title":"Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects","volume":"218","author":"Griffiths","year":"2011","journal-title":"Psychopharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib49","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.neuropharm.2011.01.017","article-title":"Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens","volume":"61","author":"Halberstadt","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib50","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00213-011-2616-6","article-title":"Behavioral effects of \u03b1,\u03b1,\u03b2,\u03b2-tetradeutero-5-MeO-DMT in rats: Comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor","volume":"221","author":"Halberstadt","year":"2012","journal-title":"Psychopharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib51","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/qjmed\/95.7.431","article-title":"Hyponatraemic states following 3,4-methylenedioxymethamphetamine (MDMA, \u2018ecstasy\u2019) ingestion","volume":"95","author":"Hartung","year":"2002","journal-title":"QJM"},{"key":"10.1016\/bs.irn.2025.02.003_bib52","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0031-6865(97)00014-9","article-title":"Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man","volume":"72","author":"Hasler","year":"1997","journal-title":"Pharmaceutica Acta Helvetiae"},{"key":"10.1016\/bs.irn.2025.02.003_bib53","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/S0140-6736(96)90196-8","article-title":"Near-fatal hyponatraemic coma due to vasopressin over-secretion after \u201cecstasy\u201d (3,4-MDMA)","volume":"347","author":"Holden","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/bs.irn.2025.02.003_bib54","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/cpt.2821","article-title":"Pharmacokinetics and pharmacodynamics of oral psilocybin administration in healthy participants","volume":"113","author":"Holze","year":"2023","journal-title":"Clin Pharmacol Thera"},{"key":"10.1016\/bs.irn.2025.02.003_bib55","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1007\/s00213-021-05978-6","article-title":"Safety pharmacology of acute LSD administration in healthy subjects","volume":"239","author":"Holze","year":"2022","journal-title":"Psychopharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib56","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1111\/bcp.13918","article-title":"Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects","volume":"85","author":"Holze","year":"2019","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib57","article-title":"Pharmacokinetics, pharmacodynamics and urinary recovery of oral lysergic acid diethylamide (LSD) administration in healthy participants","author":"Holze","year":"2023","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib58","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.biopsych.2022.08.025","article-title":"Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness: A randomized, double-blind, placebo-controlled phase II study","volume":"93","author":"Holze","year":"2023","journal-title":"Biological Psychiatry"},{"key":"10.1016\/bs.irn.2025.02.003_bib59","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41386-022-01297-2","article-title":"Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects","volume":"47","author":"Holze","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib60","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.bpsc.2024.01.007","article-title":"Serotonergic psychedelics: A comparative review of efficacy, safety, pharmacokinetics, and binding profile","volume":"9","author":"Holze","year":"2024","journal-title":"Biological Psychiatry. Cognitive Neuroscience and Neuroimaging"},{"key":"10.1016\/bs.irn.2025.02.003_bib61","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/s41386-020-00883-6","article-title":"Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects","volume":"46","author":"Holze","year":"2021","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib62","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41386-019-0569-3","article-title":"Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects","volume":"45","author":"Holze","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib63","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1124\/mol.109.058057","article-title":"Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine2B receptor agonists: Implications for drug safety assessment","volume":"76","author":"Huang","year":"2009","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib951","doi-asserted-by":"crossref","first-page":"7190","DOI":"10.1523\/JNEUROSCI.1171-11.2011","article-title":"Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time","volume":"31","author":"Huot","year":"2011","journal-title":"J Neurosci"},{"key":"10.1016\/bs.irn.2025.02.003_bib64","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1124\/jpet.111.188425","article-title":"Effects of the alpha2-adrenergic agonist clonidine on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxymethamphetamine in healthy volunteers","volume":"340","author":"Hysek","year":"2012","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/bs.irn.2025.02.003_bib65","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00213-012-2761-6","article-title":"Effects of MDMA alone and after pretreatement with reboxetine, duloxetine, clonidine, carvedilol, and doxazosin on pupillary light reflex","volume":"224","author":"Hysek","year":"2012","journal-title":"Psychopharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib66","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1111\/j.1476-5381.2012.01936.x","article-title":"Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans","volume":"166","author":"Hysek","year":"2012","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib67","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1093\/scan\/nst161","article-title":"MDMA enhances emotional empathy and prosocial behavior","volume":"9","author":"Hysek","year":"2014","journal-title":"Social Cognitive and Affective Neuroscience"},{"key":"10.1016\/bs.irn.2025.02.003_bib68","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/clpt.2011.78","article-title":"The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA (\u201cecstasy\u201d) in humans","volume":"90","author":"Hysek","year":"2011","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/bs.irn.2025.02.003_bib69","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0036476","article-title":"Duloxetine inhibits effects of MDMA (\u201cecstasy\u201d) in vitro and in humans in a randomized placebo-controlled laboratory study","volume":"7","author":"Hysek","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/bs.irn.2025.02.003_bib70","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature08506","article-title":"Predicting new molecular targets for known drugs","volume":"462","author":"Keiser","year":"2009","journal-title":"Nature"},{"key":"10.1016\/bs.irn.2025.02.003_bib71","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1038\/npp.2014.12","article-title":"Effects of MDMA and intranasal oxytocin on social and emotional processing","volume":"39","author":"Kirkpatrick","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib72","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41398-024-03116-2","article-title":"Acute dose-dependent effects of mescaline in a double-blind placebo-controlled study in healthy subjects","volume":"30","author":"Klaiber","year":"2024","journal-title":"Translat Psychiatr"},{"key":"10.1016\/bs.irn.2025.02.003_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2020.122486","article-title":"Development and validation of an LC-MS\/MS method for the bioanalysis of psilocybin\u2019s main metabolites, psilocin and 4-hydroxyindole-3-acetic acid, in human plasma","volume":"1164","author":"Kolaczynska","year":"2021","journal-title":"Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences"},{"key":"10.1016\/bs.irn.2025.02.003_bib74","doi-asserted-by":"crossref","first-page":"181","DOI":"10.4161\/oxim.2.4.9380","article-title":"Novel, unifying mechanism for mescaline in the central nervous system: Electrochemistry, catechol redox metabolite, receptor, cell signaling and structure activity relationships","volume":"2","author":"Kovacic","year":"2009","journal-title":"Oxidative Medicine Cell Longevity"},{"key":"10.1016\/bs.irn.2025.02.003_bib75","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0006-2952(00)00284-7","article-title":"Identification of the human cytochromes P450 involved in the oxidative metabolism of \"Ecstasy\"-related designer drugs","volume":"59","author":"Kreth","year":"2000","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib76","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1046\/j.1471-4159.2003.01921.x","article-title":"A complex signaling cascade links the serotonin2A receptor to phospholipase A2 activation: The involvement of MAP kinases","volume":"86","author":"Kurrasch-Orbaugh","year":"2003","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/bs.irn.2025.02.003_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2019.11.008","article-title":"Microdosing psychedelics: Motivations, subjective effects and harm reduction","volume":"75","author":"Lea","year":"2020","journal-title":"International Journal on Drug Policy"},{"key":"10.1016\/bs.irn.2025.02.003_bib78","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1038\/s41386-023-01607-2","article-title":"Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants","volume":"48","author":"Ley","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib79","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1038\/s41386-023-01607-2","article-title":"Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants","volume":"48","author":"Ley","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib80","first-page":"w14043","article-title":"Novel psychoactive substances (designer drugs): Overview and pharmacology of modulators of monoamine signaling","volume":"145","author":"Liechti","year":"2015","journal-title":"Swiss Medical Weekly"},{"key":"10.1016\/bs.irn.2025.02.003_bib81","doi-asserted-by":"crossref","first-page":"179","DOI":"10.4161\/23328940.2014.955433","article-title":"Effects of MDMA on body temperature in humans","volume":"1","author":"Liechti","year":"2014","journal-title":"Temperature"},{"key":"10.1016\/bs.irn.2025.02.003_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/S0893-133X(99)00148-7","article-title":"Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, \u201cEcstasy\u201d) are attenuated by the serotonin uptake inhibitor citalopram","author":"Liechti","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib83","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/7854_2021_270","article-title":"Dosing psychedelics and MDMA","volume":"56","author":"Liechti","year":"2022","journal-title":"Current Topics in Behavioral Neurosciences"},{"key":"10.1016\/bs.irn.2025.02.003_bib84","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0924-977X(00)00086-9","article-title":"Acute psychological and physiological effects of MDMA (\u201cEcstasy\u201d) after haloperidol pretreatment in healthy humans","volume":"10","author":"Liechti","year":"2000","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib85","series-title":"Psychological and physiological effects of extended DMT","author":"Luan","year":"2023"},{"key":"10.1016\/bs.irn.2025.02.003_bib86","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.bcp.2019.04.013","article-title":"Cytochrome P450 enzymes contribute to the metabolism of LSD to nor-LSD and 2-oxo-3-hydroxy-LSD: Implications for clinical LSD use","volume":"164","author":"Luethi","year":"2019","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib87","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1177\/0269881119844185","article-title":"Metabolites of the ring-substituted stimulants MDMA, methylone and MDPV differentially affect human monoaminergic systems","volume":"33","author":"Luethi","year":"2019","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib952","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2022.123534","article-title":"Liquid chromatography-tandem mass spectrometry method for the bioanalysis of N,N-dimethyltryptamine (DMT) and its metabolites DMT-N-oxide and indole-3-acetic acid in human plasma","volume":"1213","author":"Luethi","year":"2022","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/bs.irn.2025.02.003_bib88","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/ijnp\/pyy047","article-title":"Monoamine transporter and receptor interaction profiles in vitro predict reported human doses of novel psychoactive stimulants and psychedelics","volume":"21","author":"Luethi","year":"2018","journal-title":"The International Journal of Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2024.124123","article-title":"Derivatization-free determination of chiral plasma pharmacokinetics of MDMA and its enantiomers","volume":"1238","author":"Luethi","year":"2024","journal-title":"Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences"},{"key":"10.1016\/bs.irn.2025.02.003_bib90","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1124\/dmd.108.021543","article-title":"The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic 3,4-methylenedioxy-methamphetamine and its enantiomers","volume":"36","author":"Meyer","year":"2008","journal-title":"Drug Metabolism and Disposition: the Biological Fate of Chemicals"},{"key":"10.1016\/bs.irn.2025.02.003_bib91","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3389\/fpsyg.2018.01475","article-title":"Psychedelics, meditation, and self-consciousness","volume":"9","author":"Milli\u00e8re","year":"2018","journal-title":"Frontiers in Psychology"},{"key":"10.1016\/bs.irn.2025.02.003_bib92","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nature Medicine"},{"key":"10.1016\/bs.irn.2025.02.003_bib93","first-page":"315","article-title":"MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study","volume":"21","author":"Mitchell","year":"2023","journal-title":"Focus (Am Psychiatr Publ)"},{"key":"10.1016\/bs.irn.2025.02.003_bib94","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/0269881110378371","article-title":"The safety and efficacy of\u00b13,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: The first randomized controlled pilot study","volume":"25","author":"Mithoefer","year":"2010","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib95","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/s41593-023-01316-5","article-title":"Psychedelics promote plasticity by directly binding to BDNF receptor TrkB","volume":"26","author":"Moliner","year":"2023","journal-title":"Nature Neuroscience"},{"key":"10.1016\/bs.irn.2025.02.003_bib96","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1007\/s00213-022-06066-z","article-title":"Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants","volume":"239","author":"Muller","year":"2022","journal-title":"Psychopharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib97","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00213-007-0926-5","article-title":"Mescaline effects on rat behavior and its time profile in serum and brain tissue after a single subcutaneous dose","volume":"196","author":"P\u00e1len\u00ed\u010dek","year":"2008","journal-title":"Psychopharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib98","series-title":"The history of MDMA","article-title":"27Rise of a recreational drug","author":"Passie","year":"2023"},{"key":"10.1016\/bs.irn.2025.02.003_bib99","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1038\/s41591-023-02455-9","article-title":"Psilocybin therapy for females with anorexia nervosa: A phase 1, open-label feasibility study","volume":"29","author":"Peck","year":"2023","journal-title":"Nature Medicine"},{"key":"10.1016\/bs.irn.2025.02.003_bib100","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/ijnp\/pyx047","article-title":"Effect of psilocybin on empathy and moral decision-making","volume":"20","author":"Pokorny","year":"2017","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib101","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1007\/s00204-020-02836-w","article-title":"In vitro structure-activity relationship determination of 30 psychedelic new psychoactive substances by means of \u03b2-arrestin 2 recruitment to the serotonin 2A receptor","volume":"94","author":"Pottie","year":"2020","journal-title":"Archives of Toxicology"},{"key":"10.1016\/bs.irn.2025.02.003_bib102","doi-asserted-by":"crossref","first-page":"15444","DOI":"10.1021\/acs.analchem.9b03104","volume":"91","author":"Pottie","year":"2019","journal-title":"Analytical Chemistry"},{"key":"10.1016\/bs.irn.2025.02.003_bib103","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.cub.2016.12.030","article-title":"The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation","volume":"27","author":"Preller","year":"2017","journal-title":"Current Biology: CB"},{"key":"10.1016\/bs.irn.2025.02.003_bib104","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2023.14530","article-title":"Single-dose psilocybin treatment for major depressive disorder: A randomized clinical trial","volume":"330","author":"Raison","year":"2023","journal-title":"Journal of the American Medical Association"},{"key":"10.1016\/bs.irn.2025.02.003_bib105","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.760671","article-title":"A phase 1, dose-ranging study to assess safety and psychoactive effects of a vaporized 5-methoxy-n, n-dimethyltryptamine formulation (GH001) in healthy volunteers","volume":"12","author":"Reckweg","year":"2021","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib106","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/jnc.15587","article-title":"The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT)","volume":"162","author":"Reckweg","year":"2022","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/bs.irn.2025.02.003_bib107","doi-asserted-by":"crossref","first-page":"1133414","DOI":"10.3389\/fpsyt.2023.1133414","article-title":"A phase 1\/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression","volume":"14","author":"Reckweg","year":"2023","journal-title":"Frontiers in Psychiatry"},{"key":"10.1016\/bs.irn.2025.02.003_bib108","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/dta.1685","article-title":"Metabolism and urinary disposition of N,N-dimethyltryptamine after oral and smoked administration: A comparative study","volume":"7","author":"Riba","year":"2015","journal-title":"Drug Testing and Analysis"},{"key":"10.1016\/bs.irn.2025.02.003_bib953","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/dta.1344","article-title":"Metabolism and disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca","volume":"4","author":"Riba","year":"2012","journal-title":"Drug Test Anal"},{"key":"10.1016\/bs.irn.2025.02.003_bib109","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1124\/jpet.103.049882","article-title":"Human pharmacology of ayahuasca: Subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics","volume":"306","author":"Riba","year":"2003","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/bs.irn.2025.02.003_bib111","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1111\/bph.13128","article-title":"Pharmacological profile of novel psychoactive benzofurans","volume":"172","author":"Rickli","year":"2015","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib112","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.neuropharm.2015.08.034","article-title":"Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs)","volume":"99","author":"Rickli","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib113","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.euroneuro.2016.05.001","article-title":"Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens","volume":"26","author":"Rickli","year":"2016","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib114","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3389\/fphar.2017.00974","article-title":"Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression","volume":"8","author":"Roseman","year":"2017","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib115","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib116","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1056\/NEJMp068265","article-title":"Drugs and valvular heart disease","volume":"356","author":"Roth","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/bs.irn.2025.02.003_bib117","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejphar.2003.08.054","article-title":"Monoamine transporters and psychostimulant drugs","volume":"479","author":"Rothman","year":"2003","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib118","doi-asserted-by":"crossref","DOI":"10.1177\/02698811231225609","article-title":"Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins","author":"Rouaud","year":"2024","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib119","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1177\/02698811241246857","article-title":"Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine benzoate) in healthy participants","volume":"38","author":"Rucker","year":"2024","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib120","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/jnc.15544","article-title":"Psychedelic-inspired approaches for treating neurodegenerative disorders","volume":"162","author":"Saeger","year":"2022","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/bs.irn.2025.02.003_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109166","article-title":"Psychedelics as preventive treatment in headache and chronic pain disorders","volume":"215","author":"Schindler","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib122","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s13311-020-00962-y","article-title":"Exploratory controlled study of the migraine-suppressing effects of psilocybin","volume":"18","author":"Schindler","year":"2021","journal-title":"Neurotherapeutics"},{"key":"10.1016\/bs.irn.2025.02.003_bib123","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/head.14420","article-title":"Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Schindler","year":"2022","journal-title":"Headache"},{"key":"10.1016\/bs.irn.2025.02.003_bib124","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/FPC.0000000000000231","article-title":"CYP2D6 function moderates the pharmacokinetics and pharmacodynamics of 3,4-methylene-dioxymethamphetamine in a controlled study in healthy individuals","volume":"26","author":"Schmid","year":"2016","journal-title":"Pharmacogenetics and Genomics"},{"key":"10.1016\/bs.irn.2025.02.003_bib126","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1525\/aa.1940.42.3.02a00040","article-title":"Teonanacatl: The narcotic mushroom of the Aztecs","volume":"42","author":"Schultes","year":"1940","journal-title":"American Anthropologist"},{"key":"10.1016\/bs.irn.2025.02.003_bib127","series-title":"Plants of the gods: Their sacred, healing, and hallucinogenic powers","author":"Schultes","year":"2001"},{"key":"10.1016\/bs.irn.2025.02.003_bib128","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1021\/tx010051p","article-title":"3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans","volume":"14","author":"Segura","year":"2001","journal-title":"Chemical Research in Toxicology"},{"key":"10.1016\/bs.irn.2025.02.003_bib129","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/0269881121991792","article-title":"First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder","volume":"35","author":"Sessa","year":"2021","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib130","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2174\/138920010794233495","article-title":"Psychedelic 5-methoxy-N,N-dimethyltryptamine: Metabolism, pharmacokinetics, drug interactions, and pharmacological actions","volume":"11","author":"Shen","year":"2010","journal-title":"Current Drug Metabolism"},{"key":"10.1016\/bs.irn.2025.02.003_bib131","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bcp.2010.02.020","article-title":"Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics","volume":"80","author":"Shen","year":"2010","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib132","author":"Shulgin","year":"1991","journal-title":"PiHKAL: A Chemical Love Story"},{"key":"10.1016\/bs.irn.2025.02.003_bib133","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1476-5381.2012.02145.x","article-title":"Pharmacological characterization of designer cathinones in vitro","volume":"168","author":"Simmler","year":"2013","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib134","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0378-4347(87)80435-8","article-title":"Gas chromatographic-mass spectroscopic characterisation of the psychotomimetic indolealkylamines and their in vivo metabolites","volume":"422","author":"Sitaram","year":"1987","journal-title":"Journal of Chromatography"},{"key":"10.1016\/bs.irn.2025.02.003_bib135","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/dta.1740","article-title":"Development and validation of an LC-MS\/MS method after chiral derivatization for the simultaneous stereoselective determination of methylenedioxy-methamphetamine (MDMA) and its phase I and II metabolites in human blood plasma","volume":"7","author":"Steuer","year":"2015","journal-title":"Drug Testing and Analysis"},{"key":"10.1016\/bs.irn.2025.02.003_bib136","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1124\/dmd.115.066340","article-title":"Chiral plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine and its phase I and II metabolites following controlled administration to humans","volume":"43","author":"Steuer","year":"2015","journal-title":"Drug Metabolism and Disposition: the Biological Fate of Chemicals"},{"key":"10.1016\/bs.irn.2025.02.003_bib137","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150955","article-title":"Impact of cytochrome P450 2D6 function on the chiral blood plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA) and its phase I and II metabolites in humans","volume":"11","author":"Steuer","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/bs.irn.2025.02.003_bib138","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1177\/02698811241265352","article-title":"Methylenedioxymethamphetamine is a connectogen with empathogenic, entactogenic, and still further connective properties: It is time to reconcile \u201cthe great entactogen-empathogen debate\u201d","volume":"38","author":"Stocker","year":"2024","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib139","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/00005053-199503000-00002","article-title":"Hallucinogenic drugs in psychiatric research and treatment. Perspectives and prospects","volume":"183","author":"Strassman","year":"1995","journal-title":"The Journal of Nervous and Mental Disease"},{"key":"10.1016\/bs.irn.2025.02.003_bib140","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1001\/archpsyc.1994.03950020009001","article-title":"Dose-response study of N,N-dimethyltryptamine in humans: I. Neuroendocrine, autonomic, and cardiovascular effects","volume":"51","author":"Strassman","year":"1994","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/bs.irn.2025.02.003_bib141","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/0006-3223(95)00200-6","article-title":"Differential tolerance to biological and subjective effects of four closely spaced doses of N,N-dimethyltryptamine in humans","volume":"39","author":"Strassman","year":"1996","journal-title":"Biological Psychiatry"},{"key":"10.1016\/bs.irn.2025.02.003_bib142","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1001\/archpsyc.1994.03950020022002","article-title":"Dose-response study of N,N-dimethyltryptamine in humans: II. Subjective effects and preliminary results of a new rating scale","volume":"51","author":"Strassman","year":"1994","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/bs.irn.2025.02.003_bib143","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41386-024-01972-6","article-title":"Acute effects of R-MDMA, S-MDMA, and racemic MDMA in a randomized double-blind cross-over trial in healthy participants","volume":"50","author":"Straumann","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib144","doi-asserted-by":"crossref","first-page":"104060","DOI":"10.1016\/j.nsa.2024.104060","article-title":"Safety pharmacology of acute psilocybin administration in healthy participants","volume":"3","author":"Straumann","year":"2024","journal-title":"Neuroscience Applied"},{"key":"10.1016\/bs.irn.2025.02.003_bib145","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41386-023-01609-0","article-title":"Acute effects of MDMA and LSD co-administration in a double-blind placebo-controlled study in healthy participants","volume":"48","author":"Straumann","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib146","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1177\/0269881110382466","article-title":"Acute, subacute and long-term subjective effects of psilocybin in healthy humans: A pooled analysis of experimental studies","volume":"25","author":"Studerus","year":"2011","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib147","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1177\/0269881121998322","article-title":"Prediction of MDMA response in healthy humans: A pooled analysis of placebo-controlled studies","volume":"35","author":"Studerus","year":"2021","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib148","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/0006-2952(81)90320-8","article-title":"Characterization of eight biogenic indoleamines as substrates for type A and type B monoamine oxidase","volume":"30","author":"Suzuki","year":"1981","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib149","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1177\/02698811231190865","article-title":"The risk of chronic psychedelic and MDMA microdosing for valvular heart disease","volume":"37","author":"Tagen","year":"2023","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib150","doi-asserted-by":"crossref","first-page":"1391689","DOI":"10.3389\/fphar.2024.1391689","article-title":"In vitro and in vivo metabolism of psilocybin\u2019s active metabolite psilocin","volume":"15","author":"Thomann","year":"2024","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib151","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.114980","article-title":"Development and validation of an LC-MS\/MS method for the quantification of mescaline and major metabolites in human plasma","volume":"220","author":"Thomann","year":"2022","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/bs.irn.2025.02.003_bib153","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.106.104463","article-title":"Functional selectivity and classical concepts of quantitative pharmacology","volume":"320","author":"Urban","year":"2007","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/bs.irn.2025.02.003_bib154","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109294","article-title":"Mescaline: The forgotten psychedelic","volume":"222","author":"Vamvakopoulou","year":"2023","journal-title":"Neuropharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib155","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.funbio.2022.01.003","article-title":"Diversity, biology, and history of psilocybin-containing fungi: Suggestions for research and technological development","volume":"126","author":"Van Court","year":"2022","journal-title":"Fungal Biology"},{"key":"10.1016\/bs.irn.2025.02.003_bib955","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00213-005-0174-5","article-title":"MDMA (ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment","volume":"189","author":"Verrico","year":"2007","journal-title":"Psychopharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib156","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1177\/0269881117691569","article-title":"Safety pharmacology of acute MDMA administration in healthy subjects","volume":"31","author":"Vizeli","year":"2017","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib157","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.euroneuro.2017.01.008","article-title":"Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects","volume":"27","author":"Vizeli","year":"2017","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib158","doi-asserted-by":"crossref","first-page":"10851","DOI":"10.1038\/s41598-021-90343-y","article-title":"Genetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis","volume":"11","author":"Vizeli","year":"2021","journal-title":"Scientific Reports"},{"key":"10.1016\/bs.irn.2025.02.003_bib159","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41398-023-02477-4","article-title":"Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants","volume":"13","author":"Vogt","year":"2023","journal-title":"Translational Psychiatry"},{"key":"10.1016\/bs.irn.2025.02.003_bib160","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","article-title":"Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action","volume":"9","author":"Vollenweider","year":"1998","journal-title":"Neuroreport"},{"key":"10.1016\/bs.irn.2025.02.003_bib161","article-title":"Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial","volume":"56","author":"von Rotz","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/bs.irn.2025.02.003_bib162","doi-asserted-by":"crossref","first-page":"8221","DOI":"10.1038\/s41467-023-44016-1","article-title":"Identification of 5-HT(2A) receptor signaling pathways associated with psychedelic potential","volume":"14","author":"Wallach","year":"2023","journal-title":"Nature Communications"},{"key":"10.1016\/bs.irn.2025.02.003_bib163","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41586-024-07403-2","article-title":"Structural pharmacology and therapeutic potential of 5-methoxytryptamines","volume":"630","author":"Warren","year":"2024","journal-title":"Nature"},{"key":"10.1016\/bs.irn.2025.02.003_bib164","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1177\/0269881106065907","article-title":"Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA","volume":"20","author":"Yang","year":"2006","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/bs.irn.2025.02.003_bib165","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/00008571-200306000-00002","article-title":"Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase","volume":"13","author":"Yu","year":"2003","journal-title":"Pharmacogenetics"}],"container-title":["International Review of Neurobiology","Psychedelics in Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774225000030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774225000030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T22:52:46Z","timestamp":1750287166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0074774225000030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9780443343858"],"references-count":168,"URL":"https:\/\/doi.org\/10.1016\/bs.irn.2025.02.003","relation":{},"ISSN":["0074-7742"],"issn-type":[{"value":"0074-7742","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}